TY - JOUR
T1 - Brain mapping inflammatory arthritis related fatigue in the pursuit of novel therapeutics
AU - Stefanov, Kristian
AU - al-Wasity, Salim
AU - Parkinson, Joel Thomas
AU - Waiter, Gordon
AU - Cavanagh, Jonathan
AU - Basu, Neil
PY - 2023/2
Y1 - 2023/2
N2 - Despite advances in pharmacological treatments, chronic fatigue remains an unresolved issue for most people with inflammatory arthritis, severely disrupting their personal and working lives. Their fatigue does not strongly link with peripheral disease activity, but instead, associates with central nervous system-derived symptoms like chronic pain, sleep disturbance and depression. Thus, a neurobiological basis should be considered when pursuing novel fatigue-specific therapeutics. In this review, we will first focus on clinical imaging biomarkers that map candidate brain regions, critical in fatigue pathophysiology. Then we will evaluate neuromodulation techniques that could affect these culprit brain regions, serving as potential treatment strategies for fatigue in inflammatory arthritis. We will conclude with what work still needs to be done for neuroimaging and neuromodulation to become a part of a future clinical pathway to treat and manage fatigue.
AB - Despite advances in pharmacological treatments, chronic fatigue remains an unresolved issue for most people with inflammatory arthritis, severely disrupting their personal and working lives. Their fatigue does not strongly link with peripheral disease activity, but instead, associates with central nervous system-derived symptoms like chronic pain, sleep disturbance and depression. Thus, a neurobiological basis should be considered when pursuing novel fatigue-specific therapeutics. In this review, we will first focus on clinical imaging biomarkers that map candidate brain regions, critical in fatigue pathophysiology. Then we will evaluate neuromodulation techniques that could affect these culprit brain regions, serving as potential treatment strategies for fatigue in inflammatory arthritis. We will conclude with what work still needs to be done for neuroimaging and neuromodulation to become a part of a future clinical pathway to treat and manage fatigue.
U2 - 10.1016/S2665-9913(23)00007-3
DO - 10.1016/S2665-9913(23)00007-3
M3 - Article
SN - 2665-9913
VL - 5
SP - e99-e109
JO - The Lancet Rheumatology
JF - The Lancet Rheumatology
IS - 2
ER -